title: [A new radiation-free conditioning in bone marrow transplantation and dibromo-mannitol therapy in chronic myeloid leukemia].
abstract: A new, radiation-free, conditioning protocol, containing the original Hungarian mitobronitol (DBM) (DBM/ cytosine arabinoside/cyclosphosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from HLA identical sibling donors between 1990-1997. In spite of some prognostically disadvantageous factors (half of them were above 40 years, 10 out of 36 patients were in accelerated phase, the disease history was longer than 2 years in average) the overall survival (30/36) and the leukemia free survival rate (26/36) were in accordance with the best international results. Transplantation-related toxicity was remarkably reduced in comparison to bone marrow transplantation performed by total body irradiation/cyclophosphamide (TBI/Cy) or busulphan/cyclophosphamide (Bu/Cy) conditioning protocols. Acute graft versus host disease was present in lower percentage (9/36) and the number of serious cases was only 2/36. Chronic GVH disease, generally known to be associated with antileukemic effect (GVL), occurred in 25 of cases. Early haematological relapse among the 34 patients with functioning graft occurred in 6 patients which rate is slightly higher than reported after TBI/Cy or Bu/Cy conditioning treatment. There was no relapse among patients transplanted within one year post-diagnosis and patients having CML with accelerated phase. The leukemia free post-transplant period was in association with the chronic GVH disease and full chimeric state.
authors.affiliation: Országos Hematológiai és Immunológiai Intézet Budapest.
authors.forename: E
authors.initials: E
authors.lastname: Kelemen
authors.forename: R
authors.initials: R
authors.lastname: Dénes
authors.forename: A
authors.initials: A
authors.lastname: Barta
authors.forename: T
authors.initials: T
authors.lastname: Masszi
authors.forename: P
authors.initials: P
authors.lastname: Reményi
authors.forename: K
authors.initials: K
authors.lastname: Pálóczi
authors.forename: A
authors.initials: A
authors.lastname: Bátai
authors.forename: E
authors.initials: E
authors.lastname: Torbágyo
authors.forename: A
authors.initials: A
authors.lastname: Sipos
authors.forename: L
authors.initials: L
authors.lastname: Lengyel
authors.forename: K
authors.initials: K
authors.lastname: Jakab
authors.forename: E
authors.initials: E
authors.lastname: Gyódi
authors.forename: M
authors.initials: M
authors.lastname: Réti
authors.forename: J
authors.initials: J
authors.lastname: Földi
authors.forename: P
authors.initials: P
authors.lastname: Páldi-Haris
authors.forename: A
authors.initials: A
authors.lastname: Manuel
authors.forename: S
authors.initials: S
authors.lastname: Fekete
authors.forename: J
authors.initials: J
authors.lastname: Török
authors.forename: I
authors.initials: I
authors.lastname: Hoffer
authors.forename: J
authors.initials: J
authors.lastname: Jakab
authors.forename: G
authors.initials: G
authors.lastname: Váradi
authors.forename: G
authors.initials: G
authors.lastname: Petrányi
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002985:Clinical Protocols; D005260:Female; D006087:Graft vs Host Reaction / Q000187:drug effects; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008927:Mitobronitol / Q000627:therapeutic use*
chemical_list: D008927:Mitobronitol